This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wellens, H. J. Articles by Dassen, W. R. Search for Related Content PubMed PubMed Citation Articles by Wellens, H. J. Articles by Dassen, W. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB AMIODARONE HYDROCHLORIDE Genetics Home Reference

Circulation, Vol 69, 120-124, Copyright © 1984 by American Heart Association

ARTICLES

A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient

HJ Wellens, P Brugada, H Abdollah and WR Dassen

In 12 patients (nine with Wolff-Parkinson-White syndrome and three with ventricular tachycardia) the electrophysiologic effects of intravenous (5 mg/kg body weight in 1 min) and oral (total dose 9800 to 11,200 mg) amiodarone were studied with programmed stimulation of the heart. Intravenous and oral amiodarone had a similar (p less than .05) effect of lengthening on the effective refractory period of the atrioventricular node. Only intravenous amiodarone prolonged (p less than .05) the AH interval. Oral amiodarone was more effective than intravenous amiodarone in lengthening the anterograde effective refractory period of the accessory atrioventricular pathway. Only oral amiodarone prolonged the effective refractory period of atrium and ventricle and the HV interval, all significantly (p less than .05). Intravenous amiodarone slowed (p less than .05) the rate of circus- movement tachycardia in patients with Wolff-Parkinson-White syndrome, and further slowing was observed after oral amiodarone. Termination of tachycardia by intravenous amiodarone predicted prevention of reinitiation of tachycardia during oral amiodarone. These data indicate that intravenous and oral amiodarone do not have the same electrophysiologic effects. It is not clear whether cumulative effects, active metabolites, or both are responsible for these differences.

This article has been cited by other articles:

				D R Tomlinson, P Cherian, T R Betts, and Y Bashir Intravenous amiodarone for the pharmacological termination of haemodynamically-tolerated sustained ventricular tachycardia: is bolus dose amiodarone an appropriate first-line treatment? Emerg. Med. J., January 1, 2008; 25(1): 15 - 18. [Abstract] [Full Text] [PDF]

				P. Chevalier, A. Durand-Dubief, H. Burri, M. Cucherat, G. Kirkorian, and P. Touboul Amiodarone versus placebo and class ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis J. Am. Coll. Cardiol., January 15, 2003; 41(2): 255 - 262. [Abstract] [Full Text] [PDF]

				S. C. Verduyn, J. M. v. Opstal, J. D. Leunissen, and M. A. Vos Assessment of the Pro-Arrhythmic Potential of Anti-Arrhythmic Drugs: An Experimental Approach Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2001; 6(1): 89 - 97. [PDF]

				L Bianconi, A Castro, M Dinelli, P Alboni, A Pappalardo, E Richiardi, and M Santini Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study Eur. Heart J., August 1, 2000; 21(15): 1265 - 1273. [Abstract] [PDF]

				J. Merot, F. Charpentier, J.-M. Poirier, G. Coutris, and J. Weissenburger Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol Cardiovasc Res, November 1, 1999; 44(2): 303 - 314. [Abstract] [Full Text] [PDF]

				Y. Kreiss, Y. Sidi, and H. Gur Efficacy and safety of intravenous amiodarone in recent-onset atrial fibrillation: experience in patients admitted to a general internal medicine department Postgrad. Med. J., May 1, 1999; 75(883): 278 - 281. [Abstract] [Full Text]

				C.-T. Tai, S.-A. Chen, A.-N. Feng, W.-C. Yu, Y.-J. Chen, and M.-S. Chang Electropharmacologic Effects of Class I and Class III Antiarrhythmia Drugs on Typical Atrial Flutter : Insights Into the Mechanism of Termination Circulation, May 19, 1998; 97(19): 1935 - 1945. [Abstract] [Full Text] [PDF]

				I. Kodama, K. Kamiya, and J. Toyama Cellular electropharmacology of amiodarone Cardiovasc Res, July 1, 1997; 35(1): 13 - 29. [Full Text] [PDF]

				J. N. Nanas and J. W. Mason Pharmacokinetics and Regional Electrophysiological Effects of Intracoronary Amiodarone Administration Circulation, January 15, 1995; 91(2): 451 - 461. [Abstract] [Full Text]

				X.-J. Du, M. D. Esler, and A. M. Dart Sympatholytic Action of Intravenous Amiodarone in the Rat Heart Circulation, January 15, 1995; 91(2): 462 - 470. [Abstract] [Full Text]